AILERON THERAPEUTICS INC (ALRN) Stock Price, Quote, News and Overview
NASDAQ:ALRN - Nasdaq - US00887A2042 - Common Stock - Currency: USD
ALRN Quote, Performance and Key Statistics
2.11
+0.18 (+9.33%)
The current stock price of ALRN is 2.11 USD. In the past month the price decreased by -1.4%. In the past year, price decreased by -46.38%.
ALRN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ALRN
Company Profile
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 15 full-time employees. The company went IPO on 2017-06-29. The firm is advancing a pipeline of medicines to address unmet medical needs in orphan pulmonary and fibrosis indications. Its lead product candidate, LTI-03, is a synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. LTI-03 is being evaluated in a Phase Ib clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate, LTI-01, is a proenzyme, or zymogen, designed to slowly activate in the pleural space and break up the scar tissue, allowing for drainage of the pleural effusion. The company has completed Phase Ib and Phase IIa clinical trials for the treatment of loculated pleural effusions.
Company Info
AILERON THERAPEUTICS INC
12407 N. Mopac Expy., Suite 250 #390
Austin TEXAS 02472 US
CEO: Manuel C. Alves Aivado
Employees: 15
Company Website: https://aileronrx.com/
Investor Relations: http://investors.aileronrx.com/financial-information/annual-reports
Phone: 17378021989
AILERON THERAPEUTICS INC / ALRN FAQ
What is the stock price of AILERON THERAPEUTICS INC today?
The current stock price of ALRN is 2.11 USD. The price increased by 9.33% in the last trading session.
What is the ticker symbol for AILERON THERAPEUTICS INC stock?
The exchange symbol of AILERON THERAPEUTICS INC is ALRN and it is listed on the Nasdaq exchange.
On which exchange is ALRN stock listed?
ALRN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for AILERON THERAPEUTICS INC stock?
8 analysts have analysed ALRN and the average price target is 13.26 USD. This implies a price increase of 528.44% is expected in the next year compared to the current price of 2.11. Check the AILERON THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is AILERON THERAPEUTICS INC worth?
AILERON THERAPEUTICS INC (ALRN) has a market capitalization of 45.72M USD. This makes ALRN a Nano Cap stock.
How many employees does AILERON THERAPEUTICS INC have?
AILERON THERAPEUTICS INC (ALRN) currently has 15 employees.
What are the support and resistance levels for AILERON THERAPEUTICS INC (ALRN) stock?
AILERON THERAPEUTICS INC (ALRN) has a support level at 1.92 and a resistance level at 2.29. Check the full technical report for a detailed analysis of ALRN support and resistance levels.
Should I buy AILERON THERAPEUTICS INC (ALRN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ALRN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ALRN, evaluating the profitability, health, valuation and growth aspects
- AILERON THERAPEUTICS INC (ALRN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- AILERON THERAPEUTICS INC (ALRN) Sales and EPS estimates to see what analysts future expectations are.
- AILERON THERAPEUTICS INC (ALRN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- AILERON THERAPEUTICS INC (ALRN) Insider and Institutional Ownership to learn about the owners and their transactions.
- AILERON THERAPEUTICS INC (ALRN) Stock Chart to make your own analysis
- AILERON THERAPEUTICS INC (ALRN) Latest news and press-releases to stay up to date.
Does AILERON THERAPEUTICS INC (ALRN) stock pay dividends?
ALRN does not pay a dividend.
What is the Price/Earnings (PE) ratio of AILERON THERAPEUTICS INC (ALRN)?
AILERON THERAPEUTICS INC (ALRN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.12).
ALRN Technical Analysis
ALRN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALRN. ALRN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ALRN Financial Highlights
Over the last trailing twelve months ALRN reported a non-GAAP Earnings per Share(EPS) of -3.12. The EPS decreased by -9.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.06% | ||
| ROE | -30.71% | ||
| Debt/Equity | 0 |
ALRN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 85% to ALRN. The Buy consensus is the average rating of analysts ratings from 8 analysts.